Sakar Healthcare Signs Oncology Supply Agreement With Zydus Lifesciences; FY26 PAT Jumps 74% YoY

On Thursday, the Indian equity benchmarks traded marginally higher, with the benchmark Nifty 50 index trading above the 23,680 mark during the session. Pharmaceutical and oncology-focused stocks remained in focus amid business expansion announcements and regulatory developments. In this segment, Sakar Healthcare share price was trading at Rs 789.50 after the company announced an oncology supply agreement with Zydus Lifesciences and highlighted strong FY26 financial performance.

Sakar Healthcare Signs Agreement With Zydus Lifesciences

Sakar Healthcare informed the National Stock Exchange that it has signed an agreement with Zydus Lifesciences for the supply of oncology products across GCC countries and other emerging markets.

The company stated that with this development, it has now signed a total of 40 agreements globally in the anti-cancer segment, marking a significant milestone in its expanding international oncology business.

Regulatory And API Developments

Sakar Healthcare stated that it continues to strengthen execution capabilities in regulated markets through regulatory filings and approvals. The company has submitted 33 site variations across global partners including Accord Healthcare Limited in the UK, Heumann Pharma GmbH & Co. Generica KG in Germany, Torrent Pharma in the UK and Tillomed Laboratories in the UK.

These filings cover 18 cytotoxic molecules across markets including Germany, Italy, Norway, France, Finland, Sweden, Malta, Romania and the United Kingdom. The company has secured 5 approvals so far, including 3 from EMA and 2 from MHRA.

The company also highlighted progress in its API integration strategy, with 21 APIs developed in-house. Out of these, 16 APIs have received Written Confirmation while 2 APIs have secured CEP approvals, with additional approvals currently under review.

Sakar Healthcare FY26 Performance

For FY26, Sakar Healthcare reported consolidated revenue from operations of Rs 251.73 crore, registering a growth of around 42 per cent YoY. EBITDA stood at Rs 68.88 crore during FY26, reflecting a growth of around 39 per cent YoY.

Net profit came in at Rs 30.48 crore during FY26 compared to the previous financial year, registering a growth of around 74 per cent YoY.

For the latest reported quarter, consolidated revenue from operations stood at Rs 71.10 crore, reflecting a growth of around 42 per cent YoY. Consolidated net profit stood at Rs 11.02 crore, marking a growth of around 91 per cent YoY. EBITDA for the quarter stood at Rs 26.24 crore, while EBITDA margin improved to 37 per cent from 31 per cent reported in the corresponding quarter previous year.

Management Commentary

Commenting on the development, Mr. Sanjay Shah, Managing Director, Sakar Healthcare Ltd, said, “These achievements underscore our focus on backward integration, strengthening regulatory capabilities, and expanding across global markets. We are encouraged by the progress in our regulatory approvals and API pipeline, supported by multiple approvals and a strong set of applications under review. This strengthens our ability to scale operations, enhance market share, and deliver meaningful revenue growth in the coming years.”

About Sakar Healthcare

Sakar Healthcare Ltd is a pharmaceutical manufacturer and exporter engaged in oncology, antibiotics and general formulations. The company focuses on regulated and emerging markets through formulation manufacturing, API integration and oncology-focused product offerings. Sakar Healthcare also shared that it has globally shared 250 dossiers, completed 125 submissions and received 12 marketing authorisations across international markets.

What are your views on Sakar Healthcare’s oncology expansion and FY26 financial performance? Share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.